Nelson Capital Management LLC Purchases 4,067 Shares of Stryker Corporation $SYK

Key Points

• Nelson Capital Management LLC increased its stake in Stryker Corporation by 34.5%, acquiring an additional 4,067 shares, bringing its total to 15,863 shares.
• Stryker reported earnings of $3.13 per share in its most recent quarter, exceeding estimates, with revenue of $6.02 billion, a year-over-year increase of 11.1%.
• The company announced a quarterly dividend of $0.84 per share, which is set to be paid on October 31st, representing a 0.9% dividend yield.

Nelson Capital Management LLC increased its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 34.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,863 shares of the medical technology company's stock after purchasing an additional 4,067 shares during the period. Stryker accounts for 0.8% of Nelson Capital Management LLC's portfolio, making the stock its 25th largest holding. Nelson Capital Management LLC's holdings in Stryker were worth $6,276,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mogy Joel R Investment Counsel Inc. raised its stake in Stryker by 3.4% during the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock valued at $36,561,000 after purchasing an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. raised its stake in Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after purchasing an additional 3,341 shares during the period. Harbor Capital Advisors Inc. bought a new stake in shares of Stryker during the first quarter valued at approximately $1,840,000. Mar Vista Investment Partners LLC raised its position in shares of Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock valued at $33,572,000 after buying an additional 8,353 shares during the last quarter. Finally, United Services Automobile Association bought a new stake in shares of Stryker during the first quarter valued at approximately $2,857,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

NYSE SYK opened at $369.14 on Wednesday. The company has a market cap of $141.12 billion, a P/E ratio of 48.89, a P/E/G ratio of 2.64 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The business's 50 day moving average price is $381.50 and its 200-day moving average price is $378.86. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio is currently 44.50%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on SYK shares. BTIG Research reiterated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Rothschild Redb raised Stryker to a "hold" rating in a report on Thursday, September 18th. Evercore ISI reduced their price objective on Stryker from $418.00 to $410.00 and set an "outperform" rating on the stock in a research note on Tuesday. Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, Weiss Ratings restated a "buy (b-)" rating on shares of Stryker in a research report on Saturday, September 27th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $430.10.

Insider Buying and Selling

In other Stryker news, insider Viju Menon sold 500 shares of the company's stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.